Eiger BioPharmaceuticals (EIGR) Short Interest Ratio & Short Volume → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free EIGR Stock Alerts $1.72 -0.18 (-9.21%) (As of 04/10/2024) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Eiger BioPharmaceuticals Short Interest DataCurrent Short Volume29,800 sharesPrevious Short Volume33,600 sharesChange Vs. Previous Month-11.31%Dollar Volume Sold Short$149,149.00Short Interest Ratio / Days to Cover0.3Last Record DateMarch 31, 2024Outstanding Shares1,480,000 sharesFloat Size1,310,000 sharesShort Percent of Float2.27%Today's Trading Volume137,800 sharesAverage Trading Volume103,866 sharesToday's Volume Vs. Average133% Short Selling Eiger BioPharmaceuticals ? Sign up to receive the latest short interest report for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatEIGR Short Interest Over TimeEIGR Days to Cover Over TimeEIGR Percentage of Float Shorted Over Time Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. Eiger BioPharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202429,800 shares $149,149.00 -11.3%2.3%0.3 $5.01 3/15/202433,600 shares $172,704.00 -18.8%2.6%2.8 $5.14 2/29/202441,400 shares $231,840.00 -2.1%3.2%4.2 $5.60 2/15/202442,300 shares $240,264.00 +27.0%3.2%4.7 $5.68 1/31/202433,300 shares $216,783.00 +14.0%2.5%3.8 $6.51 1/15/202429,200 shares $214,912.00 -7.3%2.2%2.8 $7.36 Get the Latest News and Ratings for EIGR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 12/31/202331,500 shares $212,152.50 -97.1%2.1%2.9 $6.74 12/15/20231,070,000 shares $236,363.00 -7.0%N/A3.6 $0.22 11/30/20231,150,000 shares $391,115.00 +13.9%N/A3.5 $0.34 11/15/20231,010,000 shares $358,449.00 -5.6%N/A3.1 $0.35 10/31/20231,070,000 shares $279,270.00 No ChangeN/A3.1 $0.26 10/15/20231,070,000 shares $268,035.00 -7.8%N/A3.3 $0.25 9/30/20231,160,000 shares $353,800.00 -7.2%N/A4 $0.31 9/15/20231,250,000 shares $504,250.00 -0.8%N/A2.8 $0.40 8/31/20231,260,000 shares $1.09 million +4.1%N/A2.9 $0.86 8/15/20231,210,000 shares $738,100.00 +0.8%N/A2.7 $0.61 7/31/20231,200,000 shares $816,000.00 -9.8%N/A2.6 $0.68 7/15/20231,330,000 shares $1.04 million +26.7%N/A2.9 $0.78 6/30/20231,050,000 shares $739,200.00 -55.5%N/A2.1 $0.70 6/15/20232,360,000 shares $2.30 million -4.5%N/A6.2 $0.97 5/31/20232,470,000 shares $2.77 million +1.2%N/A7.4 $1.12 5/15/20232,440,000 shares $3.07 million -3.2%N/A7 $1.26 4/30/20232,520,000 shares $2.60 million -7.0%N/A4.7 $1.03 4/15/20232,710,000 shares $2.95 million +9.3%N/A4.3 $1.09 3/31/20232,480,000 shares $2.22 million +10.7%N/A3.7 $0.90 3/15/20232,240,000 shares $2.64 million +12.6%N/A3 $1.18 2/28/20231,990,000 shares $3.74 million -7.9%N/A1.7 $1.88 2/15/20232,160,000 shares $4.82 million +56.5%N/A1.9 $2.23 1/31/20231,380,000 shares $2.62 million +15.0%N/A1.2 $1.90 1/15/20231,200,000 shares $1.80 million -21.1%N/A1.3 $1.50 12/30/20221,520,000 shares $1.79 million -3.2%N/A1.7 $1.18 12/15/20221,570,000 shares $2.03 million +8.3%N/A2 $1.29 11/30/20221,450,000 shares $6.58 million -13.2%N/A2.5 $4.54 11/15/20221,670,000 shares $7.63 million -8.2%N/A4.9 $4.57 10/31/20221,820,000 shares $9.30 million -3.7%N/A5.3 $5.11 10/15/20221,890,000 shares $11.14 million -2.1%N/A5.7 $5.90 9/30/20221,930,000 shares $14.53 million +13.5%N/A6.3 $7.53 9/15/20221,700,000 shares $12.84 million -0.6%N/A5.4 $7.55 8/31/20221,710,000 shares $14.12 million -10.9%N/A5.3 $8.26 8/15/20221,920,000 shares $18.55 million -6.3%N/A5.9 $9.66“Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. EIGR Short Interest - Frequently Asked Questions What is Eiger BioPharmaceuticals' current short interest? Short interest is the volume of Eiger BioPharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 29,800 shares of EIGR short. 2.27% of Eiger BioPharmaceuticals' shares are currently sold short. Learn More on Eiger BioPharmaceuticals' current short interest. What is a good short interest percentage for Eiger BioPharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.27% of Eiger BioPharmaceuticals' floating shares are currently sold short. Is Eiger BioPharmaceuticals' short interest increasing or decreasing? Eiger BioPharmaceuticals saw a decrease in short interest in March. As of March 31st, there was short interest totaling 29,800 shares, a decrease of 11.3% from the previous total of 33,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Eiger BioPharmaceuticals' float size? Eiger BioPharmaceuticals currently has issued a total of 1,480,000 shares. Some of Eiger BioPharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Eiger BioPharmaceuticals currently has a public float of 1,310,000 shares. How does Eiger BioPharmaceuticals' short interest compare to its competitors? 2.27% of Eiger BioPharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Eiger BioPharmaceuticals: INVO Bioscience, Inc. (0.65%), Onconetix, Inc. (2.87%), Virpax Pharmaceuticals, Inc. (1.70%), Altamira Therapeutics Ltd. (3.87%), Avenue Therapeutics, Inc. (32.81%), Notable Labs, Ltd. (0.02%), Sonoma Pharmaceuticals, Inc. (1.37%), 60 Degrees Pharmaceuticals, Inc. (1.50%), CohBar, Inc. (0.59%), Cyclacel Pharmaceuticals, Inc. (3.20%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Eiger BioPharmaceuticals stock? Short selling EIGR is an investing strategy that aims to generate trading profit from Eiger BioPharmaceuticals as its price is falling. EIGR shares are trading down $0.18 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Eiger BioPharmaceuticals? A short squeeze for Eiger BioPharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EIGR, which in turn drives the price of the stock up even further. How often is Eiger BioPharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EIGR, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: INVO Bioscience Short Squeeze Onconetix Short Squeeze Virpax Pharmaceuticals Short Squeeze Altamira Therapeutics Short Squeeze Avenue Therapeutics Short Squeeze Notable Labs Short Squeeze Sonoma Pharmaceuticals Short Squeeze 60 Degrees Pharmaceuticals Short Squeeze CohBar Short Squeeze Cyclacel Pharmaceuticals Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EIGR) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity